Board Committees

Frederic Guerard, Pharm.D. has served as a member of our board of directors since September 2021. Dr. Guerard currently serves as Chief Executive Officer of Qlaris Bio, Inc., a biopharmaceutical company. He was previously Chief Executive Officer of Opthea Limited and President and Chief Executive Officer of Graybug Vision, Inc. For 20 years, Dr. Guerard held key leadership roles at Novartis AG, a multinational pharmaceutical company, including Worldwide Business Franchise Head of Ophthalmology, Global Franchise Head of Pharmaceuticals at Alcon Laboratories, Novartis Managing Director of the United Kingdom and Ireland and Country President and Managing Director of Australia and New Zealand, among others. Dr. Guerard currently serves on the boards of directors of CalciMedica, Inc., Spiral Therapeutics, and Unither Pharmaceuticals. Dr. Guerard holds a Pharm.D. and a Master of Biological and Medical Sciences from the University of Rouen, France and a Master of Marketing from HEC Paris.

Shelley Thunen has served as a member of our board of directors since November 2023. From February 2017 to January 2026, Ms. Thunen served as Chief Financial Officer of RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical technology company, and served as RxSight’s Chief Administrative Officer from January 2016 to February 2017. From January 2013 to October 2015, Ms. Thunen served as the Chief Financial Officer of Endologix, Inc. (Nasdaq: ELGX), a medical device company. From August 2010 to December 2012, Ms. Thunen served as Associate General Manager of Alcon LenSx, Inc., a medical device company. Prior to Alcon’s (NYSE: ALC) acquisition of LenSx, Inc. in August 2010, Ms. Thunen served as a board member and chair of the audit committee from April 2008 to August 2010, as well as Chief Financial Officer and Vice President, Operations from November 2009 to August 2010. Ms. Thunen joined IntraLase Corp. (Nasdaq: ILSE), a laser technology company, in May 2001 and was its Chief Financial Officer and later Executive Vice President & Chief Financial Officer until its acquisition by Advanced Medical Optics, Inc. (NYSE: EYE) in April 2007. Ms. Thunen serves on the board of directors, as audit committee chair and as a member of the nominating and corporate governance committee of AEON Biopharma, Inc. (NYSE: AEON). Ms. Thunen holds a B.A. in economics and an M.B.A. from the University of California, Irvine.

Zach Scheiner, Ph.D. has served as a member of our board of directors since  October 2020. Dr. Scheiner has been a Partner at RA Capital Management, L.P., an investment manager, since December 2025, where he joined in April 2015 as an Associate, became an Analyst in April 2017, and a Principal in December 2017. Prior to joining RA Capital, Dr. Scheiner was a Science Officer at the California Institute for Regenerative Medicine (CIRM), where he worked from September 2008 to March 2015. Dr. Scheiner currently serves on the board of directors of Nkarta Therapeutics, Inc. (Nasdaq: NKTX), SpyGlass Pharma, Inc. (Nasdaq: SPG) and two private biotechnology companies. Dr. Scheiner holds a B.S. in Molecular Biophysics and Biochemistry from Yale University and a Ph.D. in Neurobiology and Behavior from the University of Washington.

Frederic Guerard, Pharm.D. has served as a member of our board of directors since September 2021. Dr. Guerard currently serves as Chief Executive Officer of Qlaris Bio, Inc., a biopharmaceutical company. He was previously Chief Executive Officer of Opthea Limited and President and Chief Executive Officer of Graybug Vision, Inc. For 20 years, Dr. Guerard held key leadership roles at Novartis AG, a multinational pharmaceutical company, including Worldwide Business Franchise Head of Ophthalmology, Global Franchise Head of Pharmaceuticals at Alcon Laboratories, Novartis Managing Director of the United Kingdom and Ireland and Country President and Managing Director of Australia and New Zealand, among others. Dr. Guerard currently serves on the boards of directors of CalciMedica, Inc., Spiral Therapeutics, and Unither Pharmaceuticals. Dr. Guerard holds a Pharm.D. and a Master of Biological and Medical Sciences from the University of Rouen, France and a Master of Marketing from HEC Paris.

Kimberlee C. Drapkin has served a member of our board of directors since March 2024. Ms. Drapkin served as a member of the board of directors of Graphite Bio, Inc. from July 2023 and as interim president and chief executive officer of Graphite Bio, Inc. from August 2023, each through the closing of the merger with LENZ in March 2024. Ms. Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Prior to joining Graphite Bio, Ms. Drapkin was the Chief Financial Officer at Jounce Therapeutics, Inc., a biotechnology company, a position she held from August 2015 until the company’s acquisition by Concentra Biosciences, LLC in May 2023, playing a key role in building Jounce’s financial infrastructure. Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim chief financial officer for numerous early-stage biotechnology companies. Previously, she was the Chief Financial Officer at EPIX Pharmaceuticals, Inc. and also spent ten years in roles of increasing responsibility within the finance organization at Millennium Pharmaceuticals, Inc. Ms. Drapkin's career began in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Ms. Drapkin served as a member of the board of directors of Proteostasis Therapeutics, Inc. until the completion of the merger of Proteostasis and Yumanity Therapeutics, Inc., at which point she became a member of the Yumanity board of directors. Ms. Drapkin then served on the board of directors of Yumanity through the completion of its reverse merger with Kineta, Inc., and subsequently served on the board of Kineta through its acquisition by TuHura Biosciences (Nasdaq: HURA) in June 2025. She currently serves on the board of directors of Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), Imugene Limited (ASX: IMU), and Climb Bio, Inc. (Nasdaq: CLYM), where she is a member of the audit committee at all three companies. Ms. Drapkin holds a B.S. in accounting from Babson College.

Shelley Thunen has served as a member of our board of directors since November 2023. From February 2017 to January 2026, Ms. Thunen served as Chief Financial Officer of RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical technology company, and served as RxSight’s Chief Administrative Officer from January 2016 to February 2017. From January 2013 to October 2015, Ms. Thunen served as the Chief Financial Officer of Endologix, Inc. (Nasdaq: ELGX), a medical device company. From August 2010 to December 2012, Ms. Thunen served as Associate General Manager of Alcon LenSx, Inc., a medical device company. Prior to Alcon’s (NYSE: ALC) acquisition of LenSx, Inc. in August 2010, Ms. Thunen served as a board member and chair of the audit committee from April 2008 to August 2010, as well as Chief Financial Officer and Vice President, Operations from November 2009 to August 2010. Ms. Thunen joined IntraLase Corp. (Nasdaq: ILSE), a laser technology company, in May 2001 and was its Chief Financial Officer and later Executive Vice President & Chief Financial Officer until its acquisition by Advanced Medical Optics, Inc. (NYSE: EYE) in April 2007. Ms. Thunen serves on the board of directors, as audit committee chair and as a member of the nominating and corporate governance committee of AEON Biopharma, Inc. (NYSE: AEON). Ms. Thunen holds a B.A. in economics and an M.B.A. from the University of California, Irvine.

Kimberlee C. Drapkin has served a member of our board of directors since March 2024. Ms. Drapkin served as a member of the board of directors of Graphite Bio, Inc. from July 2023 and as interim president and chief executive officer of Graphite Bio, Inc. from August 2023, each through the closing of the merger with LENZ in March 2024. Ms. Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Prior to joining Graphite Bio, Ms. Drapkin was the Chief Financial Officer at Jounce Therapeutics, Inc., a biotechnology company, a position she held from August 2015 until the company’s acquisition by Concentra Biosciences, LLC in May 2023, playing a key role in building Jounce’s financial infrastructure. Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim chief financial officer for numerous early-stage biotechnology companies. Previously, she was the Chief Financial Officer at EPIX Pharmaceuticals, Inc. and also spent ten years in roles of increasing responsibility within the finance organization at Millennium Pharmaceuticals, Inc. Ms. Drapkin's career began in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Ms. Drapkin served as a member of the board of directors of Proteostasis Therapeutics, Inc. until the completion of the merger of Proteostasis and Yumanity Therapeutics, Inc., at which point she became a member of the Yumanity board of directors. Ms. Drapkin then served on the board of directors of Yumanity through the completion of its reverse merger with Kineta, Inc., and subsequently served on the board of Kineta through its acquisition by TuHura Biosciences (Nasdaq: HURA) in June 2025. She currently serves on the board of directors of Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), Imugene Limited (ASX: IMU), and Climb Bio, Inc. (Nasdaq: CLYM), where she is a member of the audit committee at all three companies. Ms. Drapkin holds a B.S. in accounting from Babson College.

Zach Scheiner, Ph.D. has served as a member of our board of directors since  October 2020. Dr. Scheiner has been a Partner at RA Capital Management, L.P., an investment manager, since December 2025, where he joined in April 2015 as an Associate, became an Analyst in April 2017, and a Principal in December 2017. Prior to joining RA Capital, Dr. Scheiner was a Science Officer at the California Institute for Regenerative Medicine (CIRM), where he worked from September 2008 to March 2015. Dr. Scheiner currently serves on the board of directors of Nkarta Therapeutics, Inc. (Nasdaq: NKTX), SpyGlass Pharma, Inc. (Nasdaq: SPG) and two private biotechnology companies. Dr. Scheiner holds a B.S. in Molecular Biophysics and Biochemistry from Yale University and a Ph.D. in Neurobiology and Behavior from the University of Washington.

Jeff George has served as Chair of our board of directors since March 2024. Mr. George has over 25 years of leadership experience across North America, Europe, and emerging markets. Since 2017, he has served as the Managing Partner of Maytal Capital, a healthcare-focused private equity investment and advisory firm he founded.

Between 2008 and 2016, Mr. George served on the Executive Committee of Novartis Group AG, a global pharmaceutical leader, first as Division Head and CEO of Sandoz, Novartis’ generic pharmaceuticals and biosimilars subsidiary, and then as Division Head and CEO of Alcon, Novartis’ then eye care subsidiary, both of which are now publicly-listed companies. Mr. George previously headed Emerging Markets for the Middle East, Africa, Southeast Asia, and CIS at Novartis Pharmaceuticals and served as Vice President and Head of Western and Eastern Europe for Novartis Vaccines. Prior to this, Mr. George held leadership roles at Gap Inc. and McKinsey & Co.

Mr. George has served on the board of directors of Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), a generics, biosimilars, and specialty pharmaceuticals company, since 2019, and as Chairman of ENYO Pharma, a privately-held, clinical-stage rare disease biotech company, since 2026. Until 2025, Mr. George also served on the boards of directors of 908 Devices (Nasdaq: MASS), a pioneer in life science diagnostics until its divestiture of its biopharma business to Repligen; Dorian Therapeutics, a pre-clinical biotech spun out of Stanford University until its sale to Altos Labs; and Lykos Therapeutics, a CNS-focused private biopharma company whose FDA-designated breakthrough therapy for PTSD has completed two Phase 3 clinical trials. Mr. George holds an M.B.A. from Harvard Business School, an M.A. from Johns Hopkins University’s School of Advanced International Studies, and a B.A. from Carleton College.